Navigation Links
FDA Selects CreatiVasc For New Innovation Pathway Program
Date:4/9/2012

GREENVILLE, S.C., April 9, 2012 /PRNewswire-USNewswire/ -- Greenville-based CreatiVasc Medical has been selected as one of the first three companies for the FDA's new Innovation Pathway program that uses collaboration with innovators to speed important medical devices to market while safeguarding patient safety.

The company has developed an innovative device for dialysis patients, called the Hemoaccess Valve System®, which has the potential to significantly reduce the complications, costly interventional surgery and suffering associated with End Stage Renal Disease patients on dialysis.

The valve system device is now in Phase I human clinical trials. Unlike current dialysis-access graft devices which are prone to clotting and early failure, the CreatiVasc technology is implanted when a patient's access graft is created and allows blood flow to be turned on through the patient's graft only when it is needed for dialysis, then turned off afterward. CreatiVasc and FDA will begin their collaboration in early May.

Company officials said the device could be on the market and available for patients within 24 months.

End Stage Renal Disease, the focus of the first Innovation Pathway, affects more than 571,000 Americans and is considered one of the most costly chronic diseases. Kidney failure and associated dialysis cost the U.S. healthcare system more than $46 billion annually.

Many dialysis patients have a Teflon tube implanted in their arm to provide vascular access for dialysis. Such tubes present a constant challenge because they frequently clot and require costly interventional surgery. According to a study published in the New England Journal of Medicine, more than 75% of dialysis grafts fail and require surgical intervention within the first year after placement. Early research shows that the CreatiVasc Hemoaccess Valve System allows selective blood flow into these grafts only when it is needed for dialysis, which is believed to reduce such universal complications.

The new FDA program will provide a totally new way for medical device companies and FDA to collaborate to assure that promising new technologies are rigorously reviewed but are also guided through its device approval process as rapidly as possible without compromising patient safety.

CreatiVasc was founded in Greenville, S.C., in 2004 by Dr. David Cull, a vascular surgeon with the Greenville Hospital System who developed the new technology after seeing first-hand the problems associated with traditional dialysis-access grafts. The company began full-time operations in 2007. The company has multiple issued patents on the device both in the U.S. and around the world.


'/>"/>
SOURCE Greenville Hospital System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility
2. ASLAN Pharmaceuticals Selects PharmaNet/i3 as Strategic Partner For Oncology Development
3. Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
4. Stryker Communications Selects Glowpoint to Enhance IP Video Platform for Operating Rooms
5. NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record
6. Biotechnology Pharmaceutical Company Selects NewCardios QTinno for Thorough QT Trial
7. Mental Health Partners Selects Stockell Healthcares InsightCS® Revenue Cycle Information Management System
8. Global Pharma Selects Semantellis Compliance Ready Social Listening Platform to Manage Corporate Reputation
9. Mammoth Hospital Selects Allscripts RCM Services
10. Inova Selects Beryl as Provider of Outsourced Patient Experience Solutions
11. WHCA Selects COMS Interactive as Affinity Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 /PRNewswire/ ... manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company designing ... disease, announced today agreements for the clinical supply of ... material at multiple sites, including Slough (UK), Visp (CH) ... --> Retinal diseases, such as age-related macular ...
Breaking Medicine Technology:
(Date:2/9/2016)... WI (PRWEB) , ... February 09, 2016 , ... ... Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has ... College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain ... won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded ... delicate neural circuits of an intact rabbit brain for extremely long-term storage using ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert ... the beginning of a new charity campaign. As part of their ongoing community ... (CASA). In the belief that children deserve a voice, and in the spirit ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and clothing, announced expansion into Canada to provide its range of unique and ... sales office in Quebec City that will provide bilingual customer service and marketing ...
Breaking Medicine News(10 mins):